Skip to content

Prediction of Pulmonary Rehabilitation Outcomes in Patients With Chronic Respiratory Disease Based on Metabolomics: a Prospective Cohort Study

Prediction of Pulmonary Rehabilitation Outcomes in Patients With Chronic Respiratory Disease Based on Metabolomics: a Prospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05681364
Enrollment
300
Registered
2023-01-12
Start date
2023-04-30
Completion date
2024-12-31
Last updated
2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, Bronchiectasis

Keywords

pulmonary rehabilitation, chronic respiratory disease, metabonomics

Brief summary

To comprehensively evaluate the pulmonary rehabilitation (PR) outcomes of patients with chronic respiratory disease (CRD), and to screen biomarkers for predicting different PR outcomes of patients with CRD using metabolomics methods, and to build a prediction model.

Interventions

profiles of metabolites in serum and exhale breath condensate (EBC) at baseline and after pulmonary rehabilitation

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* For COPD 1. Meets the Global initiative for chronic obstructive lung disease (GOLD) 2022 definition of stable COPD; 2. Age 30-75 years; 3. Lung CT images only showed chronic bronchitis and emphysema; 4. Agree to participate in the study and is able to cooperate with exhaled breath condensate collection. * For bronchiectasis 1. Lung CT showed bronchiectasis; 2. Age 18-75 years; 3. Spirometry suggests obstructive ventilatory dysfunction: forced expiratory volume in one second (FEV1) is less than 70% of forced vital capacity (FVC) post bronchodilator inhalation.

Exclusion criteria

1. Asthma or other respiratory diseases 2. History of pulmonary surgery 3. α1 antitrypsin deficiency 4. Autoimmune diseases 5. Patients with acute myocardial infarction, chronic heart failure, severe cerebral infarction or cerebral hemorrhage 6. A history of malignant disease now or within 2 years 7. History of acute exacerbation or change of medication in the past 4 weeks 8. A history of blood transfusion within the last 4 weeks 9. Drugs or alcohol abuse 10. Breastfeeding or pregnant women 11. Unable to cooperate with pulmonary rehabilitation for various reasons

Design outcomes

Primary

MeasureTime frameDescription
Pulmonary rehabilitation outcomeAt week 12 of pulmonary rehabilitationSystemic multidimensional measurements (SMM) will be used to evaluate the outcomes of PR program, the patients will be grouped in very good, good, moderate and poor responders by cluster analysis. SMM are as follows: changes in the degree of dyspnea will be measured using the modified Medical Research Council scale; the St George's Respiratory Questionnaire will be use to evaluate changes in health status; exercise performance will be measured by a 6-min walk test and a constant work-rate test; the Canadian Occupational Performance Measure will be used to identify specific problematic activities of daily life; patients scored how well they were performing the problematic activities of daily life and how satisfied they were with this level of performance; symptoms of anxiety and depression will be measured by Hospital Anxiety and Depression Scale. The efficacy of the PR program of the whole sample will be evaluated based on the minimal clinically importance.

Contacts

Primary ContactFei Wang, MD
13671304203@139.com0086 13671304203

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026